KRIT1 and cerebrocostomandibular syndrome: Since KRIT1/CCM2/PDCD10 dysfunction promotes abnormal RhoA–ROCK signaling, inhibitors of this biochemical cascade have been considered as a therapeutic strategy to treat CCMs patients [93].